Search

Jaffer A Ajani

from Houston, TX
Age ~74
Get Report
Also known as:
Jaffer Abdul Ajani, Jaffer Wendeline Ajani, Ajani Jaffer, E Ajani, S Ajani, N Ajani
Phone and address:
3927 Villanova St, Houston, TX 77002
(713) 662-3426
Related to:
Sayeeda A Ajani, 63Judy Howitt, 70Graham Howitt, 40David Howitt, 70
Connected to:
Abiodun O Ajani, 51Zaheer N Ajani, 41Zeeshan S Ajani, 36Jasmin Ajanovic, 51Muhamed Ajanovic, 52Anthonia K Ajao, 57Ayodele E Ajao, 75Diran Ajao, 60Esther N Ajao, 60Henry S Ajao, 67

Jaffer Ajani Phones & Addresses

  • 3927 Villanova St, Houston, TX 77002 (713) 662-3426 (832) 687-3426
  • 4016 Southwestern St, Houston, TX 77005 (713) 662-3426 (713) 792-2828
  • 5526 Cheena Dr, Houston, TX 77096 (713) 792-2828
  • 1330 Mac Arthur Dr, Carrollton, TX 75007 (972) 245-4129
  • 1330 Mac Arthur Dr #2307, Carrollton, TX 75007
  • Melville, NY
  • Old Westbury, NY

Work

Company: MD Anderson Cancer Center Address: 1515 Holcombe Blvd Suite 207, Houston, TX 77030 Phones: (713) 792-2121

Education

School / High School: MYSORE UNIVERSITY / MYSORE MEDICAL COLLEGE

Ranks

Certificate: American Board of Internal Medicine Certification in Internal Medicine

Professional Records

Medicine Doctors

Jaffer Ajani Photo 1

Dr. Jaffer A Ajani, Houston TX - MD (Doctor of Medicine)

View page
Address:
1515 Holcombe Blvd Suite 207, Houston, TX 77030

MD Anderson Cancer Center
1515 Holcombe Blvd Suite 207, Houston, TX 77030
(713) 792-2121 (Phone)
Hospitals:
1515 Holcombe Blvd Suite 207, Houston, TX 77030

MD Anderson Cancer Center
1515 Holcombe Blvd Suite 207, Houston, TX 77030

The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Boulevard, Houston, TX 77030
Education:
Medical Schools
MYSORE UNIVERSITY / MYSORE MEDICAL COLLEGE
Jaffer Ajani Photo 2

Jaffer A. Ajani

View page
Specialties:
Medical Oncology
Work:
MD Anderson Gastrointestinal Medical Oncology
1515 Holcombe Blvd UNIT 426, Houston, TX 77030
(713) 792-2828 (phone), (713) 745-1039 (fax)
Education:
Medical School
Indira Ghandi Med Coll, Nagpur Univ, Nagpur, Maharashtra, India
Graduated: 1973
Procedures:
Chemotherapy
Conditions:
Gastric Cancer
Malignant Neoplasm of Esophagus
Leukemia
Lung Cancer
Malignant Neoplasm of Colon
Languages:
English
Description:
Dr. Ajani graduated from the Indira Ghandi Med Coll, Nagpur Univ, Nagpur, Maharashtra, India in 1973. He works in Houston, TX and specializes in Medical Oncology. Dr. Ajani is affiliated with University Of Texas MD Anderson Cancer Center.
Jaffer Ajani Photo 3

Jaffer A Ajani, Houston TX

View page
Specialties:
Internal Medicine
Medical Oncology
Hematology & Oncology
Gastroenterology
Work:
Univ-TX MD Anderson Cancer
1515 Holcombe Blvd, Houston, TX 77030
Education:
Government Medical College, Nagpur (1971)
Jaffer Ajani Photo 4

Jaffer A Ajani, Houston TX

View page
Specialties:
Oncologist
Address:
1515 Holcombe Blvd, Houston, TX 77030
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Jaffer Ajani
Doctor
International Society of Gastr
Medical Doctor's Office
200 Broadhollow Rd, Huntington Station, NY 11747
(631) 390-8390, (800) 695-7551
Jaffer A. Ajani
Jaffer Ajani MD
Internist
1515 Holcombe Blvd, Houston, TX 77030
(713) 792-6161
Jaffer A. Ajani
Gastroenterology
University of Texas at Austin
Medical Doctor's Office Specialty Outpatient Clinic College/University
1515 Holcombe Blvd, Houston, TX 77030
PO Box 301402, Houston, TX 77230
(713) 792-2121

Publications

Isbn (Books And Publications)

Gastrointestinal Oncology: Evidence And Analysis

View page
Author

Jaffer Ajani

ISBN #

0849398657

Gastronomical [i.e. Gastrointestinal] Cancer

View page
Author

Jaffer A. Ajani

ISBN #

0387220909

Us Patents

Gene Expression Profiling Of Esophageal Carcinomas

View page
US Patent:
20100216131, Aug 26, 2010
Filed:
Dec 10, 2007
Appl. No.:
12/518441
Inventors:
Rajyalakshmi Luthra - Missouri City TX, US
Jaffer A. Ajani - Houston TX, US
Maden G. Luthra - Missouri City TX, US
International Classification:
C12Q 1/00
C07H 21/02
US Classification:
435 6, 536 2433, 536 231
Abstract:
The present invention generally regards gene expression profiling of esophageal cancers, including localized esophageal cancers. In particular, gene expression for a particular group of genes identifies individuals that are either going to be responsive to cancer therapy, for example chemotherapy and/or radiation, or that are not going to be responsive to cancer therapy. Exemplary genes having such expression profiles include, for example, PERP, S100A2, and SPRR3.

Methods For The Treatment Of Malignant Disease In Patients Using Citrulline Containing Amino Acid Solutions

View page
US Patent:
51890259, Feb 23, 1993
Filed:
May 14, 1990
Appl. No.:
7/510028
Inventors:
Jaffer Ajani - Houston TX
Bruce Grossie - Houston TX
Kenji Nishioka - Houston TX
David M. Ota - Houston TX
Assignee:
Board of Regenets, The University of Texas System - Austin TX
International Classification:
A61K 3170
A61K 31415
A61K 3140
A61K 31195
US Classification:
514 23
Abstract:
Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in the detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specfic polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red blood cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed. Also disclosed are parenteral nutritional formulations which include both citrulline and ornithine which have an arginine concentration of less than about 0. 10% by weight final concentration.

Methods And Improved Formulations For The Determination And Treatment Of Malignant Disease In Patients

View page
US Patent:
49887246, Jan 29, 1991
Filed:
Dec 9, 1988
Appl. No.:
7/282126
Inventors:
Jaffer Ajani - Houston TX
Bruce Grossie - Houston TX
Kenji Nishioka - Houston TX
David M. Ota - Houston TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 3141
A61K 3140
A61K 31195
US Classification:
514399
Abstract:
Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in the detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specific polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red blood cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed. Also disclosed are parenteral nutritional formulations which include both citrulline and ornithine which have an arginine concentration of less than about 0. 10% by weight final concentration.

Methods For The Reduction Of Difluoromethylornithine Associated Toxicity

View page
US Patent:
48594520, Aug 22, 1989
Filed:
Jan 13, 1987
Appl. No.:
7/002890
Inventors:
Jaffer Ajani - Houston TX
Bruce Grossie - Houston TX
Kenji Nishioka - Houston TX
David M. Ota - Houston TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 0000
US Classification:
424 10
Abstract:
Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in the detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specific polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red blood cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed.

Methods And Improved Formulations For The Determination And Treatment Of Malignant Disease In Patients

View page
US Patent:
51623730, Nov 10, 1992
Filed:
Aug 28, 1989
Appl. No.:
7/399778
Inventors:
Jaffer Ajani - Houston TX
Bruce Grossie - Houston TX
Kenji Nishioka - Houston TX
David M. Ota - Houston TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A01N 3744
US Classification:
514564
Abstract:
Disclosed are total parenteral nutrition formulations which include essential amino acids in combination with either arginine or ornithine, for use in detection of recurrent malignant disease in patients. Such formulations stimulate tumor-specific polyamine production to a greater extent than non-tumor related polyamine production. Additionally, such formulations were found to specifically promote an increase in red block cell putrescine levels of tumor-bearing rats. Nontumor-bearing rats were not found to be similarly reactive to these formulations. Methods for making and administering these formulations as well as their use in preventing DFMO-induced toxicity are also disclosed. The present invention also comprises formulations for use in the rejuvinati o BACKGROUND OF THE INVENTION The government may own certain rights in the present invention pursuant to NCI grant RDI CA3 4-465 and NCI grant ROI CA3 4-465.

Personalized Medicine For The Prediction Of Therapy Targeting The Hedgehog Pathway

View page
US Patent:
20150017651, Jan 15, 2015
Filed:
Jan 14, 2013
Appl. No.:
14/371062
Inventors:
- Austin TX, US
Yan Wang - Houston TX, US
Jaffer Ajani - Houston TX, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 31/675
A61K 31/5377
A61K 31/44
A61K 31/4355
A61K 31/439
G01N 33/53
A61K 31/517
US Classification:
435 612, 435 721, 435 74, 506 16, 506 18, 514 81, 5142342, 5142664, 514278, 514291, 514357
Abstract:
Methods and composition for tumor therapy, especially esophageal adenocarcinoma (EAC), are described. For example, in certain aspects methods for determining Hedgehog and mTOR signaling pathway status to select patients for administering a combination therapy of Hedgehog and mTOR signaling inhibitors are described. Furthermore, the invention provides compositions that involve testing kits for determining signaling status.
Control profile
Jaffer A Ajani from Houston, TX, age ~74 Get Report